Page 165 - CW E-Magazine (22-4-2025)

News from Abroad

RENEWED COMMITMENT

Switzerland’s Novartis lines up $23-bn investment

to boost US footprint

Swiss pharma giant, Novartis, has oral solids dosage forms and pack-
unveiled plans to invest $23-bn over the aging.
next fi ve years in US-based infrastruc-  Build two new radioligand therapy
ture, to ensure all its key medicines for (RLT) manufacturing facilities in
US patients will be made in the US. Florida and Texas.
The company said it will establish a  Expand three RLT manufacturing
research hub in San Diego, expand three facilities in Indianapolis, Millburn,
US plants and build seven new ones. and Carlsbad.

The production capacity will cover With these investments, Novartis
both active pharmaceutical ingredients will have manufacturing capacity in
(API) and biologics drug substance, the US for all its core technology plat-
as well as secondary production and forms, including small molecules and
packaging. The investment will create innovation hub in San Diego, its biologics.
roughly 1,000 new jobs at Novartis, second global R&D hub in the US.
and lead to around 4,000 other jobs in The planned $1.1-bn San Diego This new investment will bring in-
the US outside of Novartis, the company research hub, expected to open bet- ternal manufacturing of the company’s
said. ween 2028 and 2029, will serve as siRNA technology to the US for the
the epicentre of the Novartis West fi rst time.
The announcement comes in the Coast Biomedical Research pres-
backdrop of potential tariffs on drugs ence, complementing existing hubs “The US is a priority market for
imported into the US. Even though in Cambridge, MA, and Basel, Novartis, and the company has taken
pharmaceuticals were exempted from Switzerland. numerous steps over its 200-year history
tariffs, industry offi cials are still pre-  Build four new manufacturing faci- to build its US infrastructure. Over
paring for them at some point. lities in soon-to-be-determined the next 5 years, the total investment
states, including three that will in Novartis US operations is expected
Over the next fi ve years, Novartis make biologics drug substances, to be nearly $50-bn, marking a clear
said it will: drug products, device assembly and demonstration of the company’s focus
packaging, and one facility that will on the US,” the company emphasised
 Establish one biomedical research make chemical drug substances, in a press note.

Sika opens new concrete admixtures and mortars

plant in Kazakhstan

Swiss construction chemicals sup- country. Mr. Christoph Ganz, Regional portunities, and we are committed to
plier, Sika, has opened a new produc- Manager EMEA, Sika said, “The new serving this region with our innovative
tion facility in Ust-Kamenogorsk with production plant in eastern Kazakhstan solutions.”
production lines for mortar and con- will enable us to meet the growing de-
crete admixtures, as well as a modern mand from the mining and construction The construction industry in
laboratory. industries for high-performance mortars Kazakhstan is projected to grow at an
and concrete admixtures. average annual rate of 4.2% up to 2028,
The plant is Sika’s fourth factory in driven by investments in energy projects,
Kazakhstan and is located in a key in- With an abundance in minerals, water storage reservoirs, transportation
dustrial region in the eastern part of the Kazakhstan presents signifi cant op- infrastructure, and industrial parks.

Chemical Weekly April 22, 2025 165

Contents Index to Advertisers Index to Products Advertised